Commentary

Video

Clinical Implications of 3-Year OS Data With Durvalumab/Chemo in Advanced BTC

Author(s):

Milind Javle, MD, The University of Texas MD Anderson Cancer CenterRachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the clinical implications of 3-year survival data from TOPAZ-1 in advanced biliary tract cancer.

Related Videos
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
Ciara Kelly, MBBCh, BAO
Mark Agulnik, MD
Jonathan C. Trent, MD, PhD
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
Efficacy and Safety of Fruquintinib in Patients With Metastatic Colorectal Cancer According to Prior Treatment Sequence in the Refractory Setting: Results From FRESCO and FRESCO-2
5 KOLs are featured in this panel.
Salman R. Punekar, MD
Related Content
Shubham Pant, MD, MBBS
July 24th 2024

Zanidatamab Demonstrates Activity in Pretreated HER2+ Biliary Tract Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

RMC-6236 in Previously Treated PDAC
July 16th 2024

RMC-6236 Shows Activity With Favorable Toxicity Profile in Previously Treated PDAC

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

Michael Patterson
July 10th 2024

FDA Approval Sought for Another Formulation of Lutetium Lu 177 Dotatate in SSTR+ GEP-NETs

Francesco Sclafani, MD, PhD, of Institut Jules Bordet
July 8th 2024

REGINA Data Support Further Evaluation of Neoadjuvant Regorafenib, Nivolumab, and SCRT in Rectal Cancer